JP2016065086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016065086A5 JP2016065086A5 JP2015226794A JP2015226794A JP2016065086A5 JP 2016065086 A5 JP2016065086 A5 JP 2016065086A5 JP 2015226794 A JP2015226794 A JP 2015226794A JP 2015226794 A JP2015226794 A JP 2015226794A JP 2016065086 A5 JP2016065086 A5 JP 2016065086A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- apixaban
- composition according
- equal
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 27
- 229960003886 apixaban Drugs 0.000 claims 27
- 238000004090 dissolution Methods 0.000 claims 11
- 239000002775 capsule Substances 0.000 claims 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000002994 raw material Substances 0.000 claims 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 5
- 239000000969 carrier Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 4
- 239000001488 sodium phosphate Substances 0.000 claims 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Claims (31)
- 治療上有効な量のアピキサバンおよび医薬的に許容される希釈剤または担体を含む医薬組成物であって、前記アピキサバンは、結晶形の粒子を含み、この結晶形のアピキサバン粒子は、89μmと同等またはそれ以下のD90を有するものであって、
USP装置2を75rpmのパドル回転速度で37℃にて900mLの溶解媒体中で用いて測定すると、前記医薬組成物中のアピキサバンの少なくとも77重量%が前記溶解媒体中に溶解するものであり、前記溶解媒体は、0.05% ラウリル硫酸ナトリウムを含有するpH6.8の0.05M リン酸ナトリウムである、医薬組成物。 - 前記D90が、85μmと同等またはそれ以下である、請求項1または請求項2に記載の医薬組成物。
- 前記D90が、50μmと同等またはそれ以下である、請求項1または請求項2に記載の医薬組成物。
- 前記D90が、30μmと同等またはそれ以下である、請求項1または請求項2に記載の医薬組成物。
- 前記D90が、25μmと同等またはそれ以下である、請求項1または請求項2に記載の医薬組成物。
- 1重量%〜2重量%の界面活性剤をさらに含む、請求項1〜6のいずれか1項に記載の医薬組成物。
- 前記界面活性剤が、ラウリル硫酸ナトリウムである、請求項7に記載の医薬組成物。
- 2.5mg〜5mgのアピキサバンを含む、請求項1〜8のいずれか1項に記載の医薬組成物。
- 2.5mgのアピキサバンを含む、請求項1〜8のいずれか1項に記載の医薬組成物。
- 5mgのアピキサバンを含む、請求項1〜8のいずれか1項に記載の医薬組成物。
- 請求項1〜11のいずれか1項に記載の医薬組成物を含む、錠剤またはカプセル剤。
- 治療上有効な量のアピキサバンおよび医薬的に許容される希釈剤または担体を含む固形医薬組成物であって、前記医薬品が調製される原料が、89μmと同等またはそれ以下のD 90 を有する結晶形のアピキサバン粒子を含むものであって、
USP装置2を75rpmのパドル回転速度で37℃にて900mLの溶解媒体中で用いて測定すると、前記医薬組成物中のアピキサバンの少なくとも77重量%が前記溶解媒体中に溶解するものであり、前記溶解媒体は、0.05% ラウリル硫酸ナトリウムを含有するpH6.8の0.05M リン酸ナトリウムである、医薬組成物。 - 前記原料が、前記固形医薬組成物の調製時に造粒されるものである、請求項13に記載の医薬組成物。
- 前記原料が、乾式造粒によって造粒されるものである、請求項15に記載の医薬組成物。
- 前記D 90 が、85μmと同等またはそれ以下である、請求項13に記載の医薬組成物。
- 前記D 90 が、50μmと同等またはそれ以下である、請求項13に記載の医薬組成物。
- 前記D 90 が、30μmと同等またはそれ以下である、請求項13に記載の医薬組成物。
- 前記D 90 が、25μmと同等またはそれ以下である、請求項13に記載の医薬組成物。
- 2.5mg〜5mgのアピキサバンを含む、請求項13に記載の医薬組成物。
- 2.5mgのアピキサバンを含む、請求項13に記載の医薬組成物。
- 5mgのアピキサバンを含む、請求項13に記載の医薬組成物。
- 錠剤である、請求項13〜23のいずれか1項に記載の医薬組成物。
- カプセル剤である、請求項13〜23のいずれか1項に記載の医薬組成物。
- 2.5mg〜5mgのアピキサバンおよび医薬的に許容される希釈剤または担体を含む錠剤であって、前記錠剤が、原料として89μmと同等またはそれ以下のD 90 を有する結晶形のアピキサバン粒子を用いて調製されるものであって、
USP装置2を75rpmのパドル回転速度で37℃にて900mLの溶解媒体中で用いて測定すると、前記錠剤中のアピキサバンの少なくとも77重量%が前記溶解媒体中に溶解するものであり、前記溶解媒体は、0.05% ラウリル硫酸ナトリウムを含有するpH6.8の0.05M リン酸ナトリウムである、錠剤。 - 2.5mgのアピキサバンを含む、請求項26に記載の錠剤。
- 5mgのアピキサバンを含む、請求項26に記載の錠剤。
- 2.5mg〜5mgのアピキサバンおよび医薬的に許容される希釈剤または担体を含むカプセル剤であって、前記カプセル剤が、原料として89μmと同等またはそれ以下のD 90 を有する結晶形のアピキサバン粒子を用いて調製されるものであって、
USP装置2を75rpmのパドル回転速度で37℃にて900mLの溶解媒体中で用いて測定すると、前記カプセル剤中のアピキサバンの少なくとも77重量%が前記溶解媒体中に溶解するものであり、前記溶解媒体は、0.05% ラウリル硫酸ナトリウムを含有するpH6.8の0.05M リン酸ナトリウムである、カプセル剤。 - 2.5mgのアピキサバンを含む、請求項29に記載のカプセル剤。
- 5mgのアピキサバンを含む、請求項29に記載のカプセル剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30805610P | 2010-02-25 | 2010-02-25 | |
US61/308,056 | 2010-02-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012555127A Division JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016209347A Division JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016065086A JP2016065086A (ja) | 2016-04-28 |
JP2016065086A5 true JP2016065086A5 (ja) | 2016-08-25 |
JP6033945B2 JP6033945B2 (ja) | 2016-11-30 |
Family
ID=43901603
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012555127A Active JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
JP2015226794A Active JP6033945B2 (ja) | 2010-02-25 | 2015-11-19 | アピキサバン製剤 |
JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012555127A Active JP5846647B2 (ja) | 2010-02-25 | 2011-02-24 | アピキサバン製剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016209347A Active JP6192078B2 (ja) | 2010-02-25 | 2016-10-26 | アピキサバン製剤 |
JP2017149644A Active JP6577980B2 (ja) | 2010-02-25 | 2017-08-02 | アピキサバン製剤 |
Country Status (31)
Country | Link |
---|---|
US (5) | US9326945B2 (ja) |
EP (7) | EP3662899A1 (ja) |
JP (4) | JP5846647B2 (ja) |
KR (4) | KR20170126016A (ja) |
CN (3) | CN109602716A (ja) |
AU (1) | AU2011220775B2 (ja) |
BR (1) | BR112012021337A8 (ja) |
CA (1) | CA2791171C (ja) |
CO (1) | CO6640207A2 (ja) |
CY (5) | CY1117434T1 (ja) |
DK (5) | DK3246021T3 (ja) |
ES (5) | ES2767848T3 (ja) |
HK (5) | HK1224216A1 (ja) |
HR (5) | HRP20160179T1 (ja) |
HU (4) | HUE027168T2 (ja) |
IL (3) | IL309564A (ja) |
IN (1) | IN2012DN06587A (ja) |
LT (4) | LT3246021T (ja) |
MX (3) | MX2012009244A (ja) |
NZ (1) | NZ601738A (ja) |
PE (3) | PE20130378A1 (ja) |
PL (5) | PL2538925T3 (ja) |
PT (5) | PT3246021T (ja) |
RS (5) | RS59810B1 (ja) |
RU (1) | RU2685724C2 (ja) |
SG (2) | SG182750A1 (ja) |
SI (5) | SI2538925T1 (ja) |
SM (1) | SMT201600049B (ja) |
TR (1) | TR201903195T4 (ja) |
WO (1) | WO2011106478A2 (ja) |
ZA (1) | ZA201205807B (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3662899A1 (en) * | 2010-02-25 | 2020-06-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban formulations |
US20150018386A1 (en) * | 2012-03-06 | 2015-01-15 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
CA2873949A1 (en) * | 2012-05-24 | 2013-11-28 | Ratiopharm Gmbh | Dosage forms comprising apixaban and matrix former |
AU2013323435C1 (en) * | 2012-09-26 | 2018-04-12 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban liquid formulations |
CN102908324A (zh) * | 2012-10-31 | 2013-02-06 | 南京正科制药有限公司 | 一种阿哌沙班片 |
EP2752414A1 (en) | 2013-01-04 | 2014-07-09 | Sandoz AG | Crystalline form of apixaban |
CZ2013305A3 (cs) | 2013-04-23 | 2014-11-05 | Zentiva, K.S. | Nové krystalické formy APIXABANU a způsob jejich přípravy |
WO2014203275A2 (en) * | 2013-06-18 | 2014-12-24 | Cadila Healthcare Limited | An improved process for the preparation of apixaban and intermediates thereof |
EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
CN103830199A (zh) * | 2014-03-24 | 2014-06-04 | 重庆东得医药科技有限公司 | 含阿哌沙班的药用制剂及其制备方法 |
CN104316637B (zh) * | 2014-10-30 | 2016-08-17 | 江苏宝众宝达药业有限公司 | 高效液相色谱法测定阿哌沙班清洗残留量 |
US9603846B2 (en) | 2014-11-25 | 2017-03-28 | Cadila Healthcare Limited | Process for the preparation of apixaban |
AU2016259897A1 (en) * | 2015-05-08 | 2017-08-17 | Wockhardt Limited | Stable pharmaceutical compositions comprising antibacterial agent |
WO2017088841A1 (en) | 2015-11-26 | 2017-06-01 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
CN106913528A (zh) * | 2015-12-25 | 2017-07-04 | 中美华世通生物医药科技(武汉)有限公司 | 阿哌沙班微丸及其制备方法 |
WO2017121340A1 (zh) * | 2016-01-12 | 2017-07-20 | 广东东阳光药业有限公司 | 阿哌沙班固体组合物及其制备方法 |
EP3195860A1 (de) * | 2016-01-22 | 2017-07-26 | STADA Arzneimittel AG | Verfahren zur herstellung eines apixaban-granulates |
WO2017163170A1 (en) * | 2016-03-21 | 2017-09-28 | Sun Pharmaceutical Industries Limited | Pharmaceutical composition comprising apixaban |
WO2017182908A1 (en) * | 2016-04-18 | 2017-10-26 | Emcure Pharmaceuticals Limited | Pharmaceutical compositions of apixaban |
EP3243505A1 (en) | 2016-05-13 | 2017-11-15 | Zaklady Farmaceutyczne Polpharma SA | A pharmaceutical composition comprising amorphous apixaban |
CN106822006B (zh) * | 2016-06-08 | 2020-08-28 | 北京普德康利医药科技发展有限公司 | 一种阿哌沙班片及其制备方法 |
WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
MX2019003339A (es) * | 2016-09-24 | 2019-06-03 | Kbp Biosciences Co Ltd | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso. |
CN106420651B (zh) * | 2016-09-28 | 2019-03-08 | 乐普药业股份有限公司 | 一种阿哌沙班片的制备方法 |
US11510909B2 (en) | 2017-02-17 | 2022-11-29 | Unichem Laboratories Ltd. | Pharmaceutical composition of apixaban |
JP7044115B2 (ja) | 2017-11-27 | 2022-03-30 | 三菱ケミカル株式会社 | ゴム含有グラフト重合体組成物を含む熱可塑性樹脂の樹脂改質用組成物、ゴム含有グラフト重合体含有樹脂組成物およびその成形体 |
KR20190075566A (ko) | 2017-12-21 | 2019-07-01 | 전자부품연구원 | 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법 |
TR201722523A2 (tr) | 2017-12-28 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar |
CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
WO2019204193A1 (en) | 2018-04-16 | 2019-10-24 | Bristol-Myers Squibb Company | Apixaban formulations |
KR20190130411A (ko) * | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
EP3838265A4 (en) | 2018-08-14 | 2022-05-11 | Jiangsu Hengrui Medicine Co., Ltd. | INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION |
EP3666773A1 (en) | 2018-12-11 | 2020-06-17 | KRKA, D.D., Novo Mesto | Process for preparing apixaban |
EP3669866A1 (en) | 2018-12-19 | 2020-06-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apixaban |
CN111377915B (zh) * | 2018-12-30 | 2023-10-24 | 鲁南制药集团股份有限公司 | 一种吡唑并-吡啶酮化合物晶型d |
CN109464415B (zh) * | 2019-01-09 | 2021-08-17 | 常州恒邦药业有限公司 | 阿哌沙班药物组合物及其制备方法 |
CN111214442B (zh) * | 2020-02-13 | 2021-12-10 | 山东百诺医药股份有限公司 | 一种阿哌沙班共微粉化物 |
CN111494326A (zh) * | 2020-04-11 | 2020-08-07 | 南京正大天晴制药有限公司 | 一种阿哌沙班片及其制备方法 |
WO2022115052A1 (en) * | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Improved wet granulation processes for apixaban comprising formulations |
WO2022150030A2 (en) | 2021-01-08 | 2022-07-14 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet of apixaban |
TR202100250A2 (tr) | 2021-01-08 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Api̇ksaban i̇çeren fi̇lm kapli tablet |
GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
CN100340559C (zh) | 1998-12-23 | 2007-10-03 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为凝血因子xa抑制剂的含氮杂双环 |
ATE544750T1 (de) | 2001-09-21 | 2012-02-15 | Bristol Myers Squibb Co | Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
US7434502B2 (en) | 2004-07-21 | 2008-10-14 | Husqvarna Outdoor Products Inc. | Bar knob with cam-operated locking mechanism |
US20060016084A1 (en) * | 2004-07-24 | 2006-01-26 | Ching-Lin Liao | Laser-Based datum instrument |
US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US20060160841A1 (en) | 2005-01-19 | 2006-07-20 | Chenkou Wei | Crystallization via high-shear transformation |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
US9034381B2 (en) | 2005-11-10 | 2015-05-19 | Alphapharm Pty Ltd | Process to control particle size |
US20070259913A1 (en) | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
TW200824723A (en) * | 2006-09-12 | 2008-06-16 | Glaxo Group Ltd | Pharmaceutical composition |
FI20080351A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
US8865692B2 (en) * | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
WO2009135946A1 (en) * | 2008-05-09 | 2009-11-12 | Atacama Labs Oy | Method and apparatus for dry granulation |
WO2010003811A1 (en) | 2008-07-11 | 2010-01-14 | Basf Se | Amphiphilic proteins as morphology modifiers |
US20100018486A1 (en) * | 2008-07-22 | 2010-01-28 | Hung-Tao Liu | Cathode energy fuel-saving device |
US11033523B2 (en) * | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
EP2442791B1 (en) | 2009-06-16 | 2019-11-27 | Pfizer Inc. | Dosage forms of apixaban |
EP3662899A1 (en) * | 2010-02-25 | 2020-06-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Apixaban formulations |
JP6092629B2 (ja) * | 2010-03-10 | 2017-03-08 | ルピン・リミテッドLupin Limited | リファキシミン使用準備済懸濁液 |
-
2011
- 2011-02-24 EP EP20151141.7A patent/EP3662899A1/en active Pending
- 2011-02-24 HU HUE11707284A patent/HUE027168T2/en unknown
- 2011-02-24 LT LTEP17175864.2T patent/LT3246021T/lt unknown
- 2011-02-24 PE PE2012001362A patent/PE20130378A1/es not_active Application Discontinuation
- 2011-02-24 WO PCT/US2011/025994 patent/WO2011106478A2/en active Application Filing
- 2011-02-24 PT PT171758642T patent/PT3246021T/pt unknown
- 2011-02-24 IN IN6587DEN2012 patent/IN2012DN06587A/en unknown
- 2011-02-24 RS RS20200017A patent/RS59810B1/sr unknown
- 2011-02-24 NZ NZ601738A patent/NZ601738A/en unknown
- 2011-02-24 MX MX2012009244A patent/MX2012009244A/es active IP Right Grant
- 2011-02-24 KR KR1020177031997A patent/KR20170126016A/ko not_active IP Right Cessation
- 2011-02-24 JP JP2012555127A patent/JP5846647B2/ja active Active
- 2011-02-24 KR KR1020217031947A patent/KR20210124532A/ko not_active Application Discontinuation
- 2011-02-24 PL PL11707284T patent/PL2538925T3/pl unknown
- 2011-02-24 PT PT171757883T patent/PT3251660T/pt unknown
- 2011-02-24 HU HUE17178613A patent/HUE047140T2/hu unknown
- 2011-02-24 RS RS20191493A patent/RS59593B1/sr unknown
- 2011-02-24 PE PE2015002402A patent/PE20160042A1/es unknown
- 2011-02-24 HU HUE15190823A patent/HUE043932T2/hu unknown
- 2011-02-24 ES ES17175864T patent/ES2767848T3/es active Active
- 2011-02-24 AU AU2011220775A patent/AU2011220775B2/en active Active
- 2011-02-24 RS RS20160088A patent/RS54559B1/en unknown
- 2011-02-24 MX MX2017016605A patent/MX364938B/es unknown
- 2011-02-24 DK DK17175864.2T patent/DK3246021T3/da active
- 2011-02-24 IL IL309564A patent/IL309564A/en unknown
- 2011-02-24 SG SG2012055547A patent/SG182750A1/en unknown
- 2011-02-24 KR KR1020237035193A patent/KR20230149861A/ko active Application Filing
- 2011-02-24 CN CN201810769647.9A patent/CN109602716A/zh active Pending
- 2011-02-24 DK DK15190823.3T patent/DK3017811T3/en active
- 2011-02-24 LT LT17175788T patent/LT3251660T/lt unknown
- 2011-02-24 ES ES17175788T patent/ES2758031T3/es active Active
- 2011-02-24 SI SI201130742T patent/SI2538925T1/sl unknown
- 2011-02-24 CN CN201811354155.XA patent/CN109602713A/zh active Pending
- 2011-02-24 DK DK11707284.3T patent/DK2538925T3/en active
- 2011-02-24 LT LT17178613T patent/LT3257500T/lt unknown
- 2011-02-24 US US13/579,796 patent/US9326945B2/en active Active
- 2011-02-24 EP EP15190823.3A patent/EP3017811B1/en not_active Revoked
- 2011-02-24 EP EP17178613.0A patent/EP3257500B1/en not_active Revoked
- 2011-02-24 SI SI201131827T patent/SI3246021T1/sl unknown
- 2011-02-24 PL PL17175864T patent/PL3246021T3/pl unknown
- 2011-02-24 RU RU2012140690A patent/RU2685724C2/ru active
- 2011-02-24 SG SG10201501349VA patent/SG10201501349VA/en unknown
- 2011-02-24 TR TR2019/03195T patent/TR201903195T4/tr unknown
- 2011-02-24 CN CN201180011229XA patent/CN102770126A/zh active Pending
- 2011-02-24 EP EP17175788.3A patent/EP3251660B1/en not_active Revoked
- 2011-02-24 LT LTEP15190823.3T patent/LT3017811T/lt unknown
- 2011-02-24 MX MX2015007763A patent/MX353145B/es unknown
- 2011-02-24 RS RS20190290A patent/RS58699B1/sr unknown
- 2011-02-24 DK DK17175788T patent/DK3251660T3/da active
- 2011-02-24 HU HUE17175788A patent/HUE047139T2/hu unknown
- 2011-02-24 ES ES11707284.3T patent/ES2562279T3/es active Active
- 2011-02-24 EP EP17175864.2A patent/EP3246021B1/en not_active Revoked
- 2011-02-24 PL PL17175788T patent/PL3251660T3/pl unknown
- 2011-02-24 EP EP11707284.3A patent/EP2538925B1/en not_active Revoked
- 2011-02-24 ES ES15190823T patent/ES2714363T3/es active Active
- 2011-02-24 SI SI201131813T patent/SI3257500T1/sl unknown
- 2011-02-24 ES ES17178613T patent/ES2757603T3/es active Active
- 2011-02-24 KR KR1020127022152A patent/KR101796300B1/ko active IP Right Review Request
- 2011-02-24 PT PT171786130T patent/PT3257500T/pt unknown
- 2011-02-24 PE PE2020000316A patent/PE20210468A1/es unknown
- 2011-02-24 SI SI201131665T patent/SI3017811T1/sl unknown
- 2011-02-24 SI SI201131811T patent/SI3251660T1/sl unknown
- 2011-02-24 DK DK17178613T patent/DK3257500T3/da active
- 2011-02-24 PT PT117072843T patent/PT2538925E/pt unknown
- 2011-02-24 BR BR112012021337A patent/BR112012021337A8/pt not_active Application Discontinuation
- 2011-02-24 PL PL17178613T patent/PL3257500T3/pl unknown
- 2011-02-24 EP EP19199147.0A patent/EP3643301A1/en active Pending
- 2011-02-24 CA CA2791171A patent/CA2791171C/en active Active
- 2011-02-24 PT PT15190823T patent/PT3017811T/pt unknown
- 2011-02-24 RS RS20191468A patent/RS59576B1/sr unknown
- 2011-02-24 PL PL15190823T patent/PL3017811T3/pl unknown
-
2012
- 2012-07-22 IL IL221064A patent/IL221064A0/en unknown
- 2012-08-01 ZA ZA2012/05807A patent/ZA201205807B/en unknown
- 2012-09-05 CO CO12152138A patent/CO6640207A2/es not_active Application Discontinuation
-
2013
- 2013-07-02 HK HK16112621.4A patent/HK1224216A1/zh unknown
- 2013-07-02 HK HK13107697.6A patent/HK1180248A1/zh not_active IP Right Cessation
-
2015
- 2015-11-19 JP JP2015226794A patent/JP6033945B2/ja active Active
-
2016
- 2016-02-17 SM SM201600049T patent/SMT201600049B/xx unknown
- 2016-02-19 HR HRP20160179TT patent/HRP20160179T1/hr unknown
- 2016-03-07 CY CY20161100194T patent/CY1117434T1/el unknown
- 2016-03-31 US US15/086,447 patent/US20160243101A1/en not_active Abandoned
- 2016-10-26 JP JP2016209347A patent/JP6192078B2/ja active Active
-
2017
- 2017-03-30 US US15/474,236 patent/US20170202824A1/en not_active Abandoned
- 2017-03-30 US US15/474,264 patent/US20170202825A1/en not_active Abandoned
- 2017-04-27 IL IL251991A patent/IL251991A0/en unknown
- 2017-08-02 JP JP2017149644A patent/JP6577980B2/ja active Active
-
2018
- 2018-03-14 HK HK18103544.5A patent/HK1243947B/zh unknown
- 2018-03-14 HK HK18103542.7A patent/HK1243945B/zh unknown
- 2018-03-14 HK HK18103543.6A patent/HK1243946A1/zh unknown
-
2019
- 2019-02-28 CY CY20191100249T patent/CY1121597T1/el unknown
- 2019-03-05 HR HRP20190430TT patent/HRP20190430T8/hr unknown
- 2019-11-15 HR HRP20192064TT patent/HRP20192064T1/hr unknown
- 2019-11-18 HR HRP20192069TT patent/HRP20192069T1/hr unknown
- 2019-11-21 CY CY20191101226T patent/CY1122382T1/el unknown
- 2019-11-22 CY CY20191101231T patent/CY1122384T1/el unknown
-
2020
- 2020-01-13 HR HRP20200046TT patent/HRP20200046T1/hr unknown
- 2020-01-28 CY CY20201100074T patent/CY1122529T1/el unknown
- 2020-05-14 US US15/931,910 patent/US20200375968A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016065086A5 (ja) | ||
JP2012031147A5 (ja) | ||
IL283152B2 (en) | Preparations containing a high dose of a tetracyclic compound, methods for their preparation and their uses | |
JP6875407B2 (ja) | Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
JP2012031131A5 (ja) | ||
JP2018534348A5 (ja) | ||
JP2015535289A5 (ja) | ||
JP2015078230A5 (ja) | ||
JP2016540021A5 (ja) | ||
CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
JP2009235073A5 (ja) | ||
UA110853C2 (uk) | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування | |
JPS59222475A (ja) | 二相薬剤組成物 | |
HRP20220332T1 (hr) | Farmaceutski pripravak koji sadrži drospirenon za uporabu kao kontraceptiv | |
CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
JP2008516004A5 (ja) | ||
ES2606307T3 (es) | Producto de co-micronización que comprende acetato de ulipristal | |
CN106176640B (zh) | 一种含枸橼酸托法替布的药物组合物及其制备方法 | |
JP2018527305A5 (ja) | ||
WO2011160541A1 (zh) | 托伐普坦固体分散体及其制备方法 | |
CN104721156A (zh) | 一种含利伐沙班的片剂 | |
EP2432459A2 (en) | Oral compositions of celecoxib | |
JPWO2013100112A1 (ja) | アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物 | |
JP2014527506A5 (ja) | ||
RU2020102280A (ru) | Фармацевтическая композиция и способ ее получения |